Urology · Overactive Bladder
The submission of an ANDA for Mirabegron by Deva Holding signifies a new competitive threat in the overactive bladder treatment market. This could disrupt existing market dynamics and necessitate strategic adjustments from current players to maintain their competitive edge.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 8/2/2026, 6:32:49 PM
Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The submission of an ANDA for Mirabegron by Deva Holding signifies a new competitive threat in the overactive bladder treatment market. This could disrupt existing market dynamics and necessitate strategic adjustments from current players to maintain their competitive edge. Regulatory context from FDA (Companies that Have Not Submitted Drug Amount Reports) supports the near-term read. Assessment grounded in 16 ranked evidence items (4 high-relevance).
Portfolio teams should assess the implications of a new entrant in the Mirabegron market and consider strategies to maintain competitive advantage. The strongest clinical anchor is Hydrus® Microstent New Enrollment Post-Approval Study (ClinicalTrials.gov), moderate corpus alignment. In Urology · Overactive Bladder, 4 regulatory and 3 competitive items passed relevance filtering for Mirabegron.
The most relevant competitive pressure comes from FDA Approves Pregabalin Application ANDA219593 by Unichem (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Approves Glycerol Phenylbutyrate Application by Lupin. This submission indicates Deva Holding's entry into the competitive landscape for overactive bladder treatments, potentially impacting existing players.
Regulatory risk is concentrated around Companies that Have Not Submitted Drug Amount Reports (FDA). Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, PMDA. The FDA's standard review process for this application could influence the timeline for market entry and subsequent competitive actions, impacting regulatory strategies for other companies.
Companies that Have Not Submitted Drug Amount Reports
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceAdvancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceRare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source[IBENTO][IBENTO]PMDA-ATC Blood Products Seminar 2026 for PPWG Applications open.
PMDAmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceVenlafaxine Combined With Education and Behavioral Intervention for Bladder Pain Syndrome
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNeurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRandomized, Controlled, Exploratory Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Effect of Osteoporotic Medications on Vertebral Bone Quality Score
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Approves Pregabalin Application ANDA219593 by Unichem
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Glycerol Phenylbutyrate Application by Lupin
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves QLONILIK (Clonidine Hydrochloride) NDA221094
Humanexa Signalsmedium relevance
Moderate corpus alignment
A comprehensive review on Jiao-tai-wan: Traditional application, pharmacokinetics, and therapeutic mechanisms in multiple disorders.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View sourceSanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceThe dual role of exosomes in renal fibrosis and their potential for clinical translational applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe submission of an ANDA for Mirabegron by Deva Holding signifies a new competitive threat in the overactive bladder treatment market. This could disrupt existing market dynamics and necessitate strategic adjustments from current players to maintain their competitive edge.
The entry of Deva Holding could lead to increased competition, potentially affecting market share and pricing strategies for existing products in the overactive bladder segment.
The FDA's standard review process for this application could influence the timeline for market entry and subsequent competitive actions, impacting regulatory strategies for other companies.
Monitor the progress of the FDA review and any subsequent approvals or market entries by Deva Holding.
Track for follow-up milestones; no immediate action required.